Forge Biologics continues its hot streak with $90M round to boost gene therapy manufacturing services
Over the past two years, the Ohio-based gene therapy manufacturer Forge Biologics has managed to get a large amount of capital to scale up its AAV production capabilities. And as the field continues to grow, the company looks to grow along with it.
The company announced Monday that it has raised $90 million in a Series C funding round, bringing the total amount raised so far to $330 million. In an interview with Endpoints News, Forge Biologics CEO Tim Miller said that the round itself took only a few months to put together as firms had approached Forge to participate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.